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Conclusions: This initial feasibility and safety study of renal nerve denervation mediated
by low and intermediate -radiation dosages indicates that this approach can cause
substatntial nerve damage while avoiding significant damage to the renal artery.
TCT-208
Catheter-based renal sympathetic denervation – results of the heidelberg
registry
Michael Kirchberger1, Erwin Blessing1, Hugo Katus1, Britta Vogel1, Martin Zeier1
1University of Heidelberg, Heidelberg, Germany
Background: Renal sympathetic denervation is a novel treatment option in patients with
treatment resistant hypertension. Registry data allow to evaluate safety and efficacy in a
real-world szenario.
Methods: 53 consecutive patients with treatment resistant hypertension underwent renal
sympathetic denervation with the Symplicity radiofrequency based catheter. At baseline,
mean office blood pressure was 17122/9317 mm Hg. The mean number of
antihypertensive agents was 5.0.
Results: At 6 months follow up, office systolic blood pressure improved to 15118 mm
Hg (minus 20 mm Hg compared to baseline; p0.0001), the diastolic blood pressure to
8611 mm Hg (minus 7 mm Hg compared to baseline, p0.001). The response rate,
defined as reduction of office systolic blood pressure of 10 mm Hg was 66%. In 9
Patients (17%), number of dosage of antihypertensive agents could be reduced. The mean
number of ablations points per kidney was 4.3. There was no correlation between the
number of ablation points and blood pressure response (r 0,25, pns).
Conclusions: Renal sympathetic denervation with the Simplicity systems results in a
significant reduction of office systolic and diastolic blood pressure reduction in patients
with treatment resistant hypertension. Effects on blood pressure were somewhat less
profound than reported in the Symplicity trial program, reflecting a real world szenario
with more liberal use of the method. Interestingly, there was no correlation between the
number of ablation points and blood pressure response.
TCT-209
Durable Reduction In Blood Pressure In the First Cohort of Patients Treated
With Renal Sympathetic Denervation Therapy For Resistant Hypertension
Sonny Palmer1, Michael Stokes1, Christopher Judkins1, Paul Williams1,
Robert Whitbourn1
1St Vincent’s Hospital, Melbourne, Victoria, Australia
Background: Resistant hypertension is associated with significant cardiovascular mor-
bidity and mortality and it poses a significant treatment challenge for physicians. The
treatment of resistant hypertension by renal sympathetic denervation (RD) has demon-
strated excellent short-term reductions in blood pressure (BP) at six-months as reported by
the Symplicity HTN-2 Investigators. The future role of RD is evolving and long-term
results will clarify it’s durability. Here we assess the long-term results in the first cohort
of patients to be treated with RD in Australia.
Methods: We compared the baseline office-based BP to long-term follow-up office-based
BP, number of prescribed anti-hypertensive medications, major adverse cardiac and
cerebrovascular events (MACCE) and hospital admissions in 8 patients whom had
undergone RD from July 2007 to January 2008.
Results: Our cohort had a mean follow-up of 43 months and we found that office-based
BP measurements were reduced by a mean of 30/9 mmHg when compared to baseline
measurements (p0.003 systolic; p0.09 diastolic). The mean number of prescribed
anti-hypertensive medications remained stable throughout the follow-up period (4.88
medications pre-treatment vs 4.1 medications at follow-up; pNS). Two patients required
hospitalisation for late cerebrovascular events. There were no cardiac events reported.
Conclusions: This is the longest reported follow-up of renal sympathetic denervation
patients. We have demonstrated a significant and durable decrease in blood pressure.
However, there has been no reduction in the number of prescribed anti-hypertensive
medications.
TCT-210
Decrease of the norepinephrine release from sympathetic nerves during renal
denervation
Klaus Tiroch1, Ina Schmitz1, Melchior Seyfarth2, Jacek Szymanski1
1HELIOS Klinkum, Wuppertal, Germany, 2HelELIOS Klinikum, Wuppertal,
Germany
Background: Renal denervation (RDN) is a promising new treatment option for
pronounced hypertension refractory to medical therapy. Interestingly, only 70-80% of
patients have a relevant reduction in blood pressure (BP) three to six months after RDN
when assessed by systematic 24h BP measurements. No variables have been identified to
date predicting the BP response.
Methods: We assessed 11 patients with bilateral renal denervation for the changes of pre-
and postprocedural norepinephrine (NE) and epinephrine (E) levels measured directly
from the renal artery (RA) and vein (RV). We defined the respective spillover for NE
and E as the difference RV-RA and compared this difference before and after the
procedure.
Results: We assessed NE and E for 88 probes (11 patients x 2 (bilateral probes) x 2 (RA
and RV) x 2(pre- and post-procedural)). There was a significant decrease of the NE
RV-RA spill-over comparing pre- with post-procedural levels (184pg/ml180 decrease
to 97pg/ml137, P0.03 for paired t-test). There was no significant change in the
epinephrine levels during the procedure under conscious sedation (56pg/ml192 com-
pared to 29pg/ml171, P0.62 for paired t-test). The pre-post NE RV-RA was even
more pronounced when the median values were compared (P  0.02).
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Conclusions: The decrease of NE veno-arterial difference is a directly assessable
physiologic marker reflecting the effects of RDN with reduced renal NE release from
sympathetic nerves. The current systematic follow-up at 3 and 6 months of our patients
will allow the evaluation for a possible association of the pre-post NE RV-RA with the
BP response.
TCT-211
Ambulatory blood pressure and dipping-pattern after catheter-based renal
sympathetic denervation in patients with resistant hypertension
Felix Mahfoud1, Christian Ukena1, Bodo Cremers1, Ulrich Laufs1,
Bruno Scheller2, Markus Schlaich3, Michael Böhm1
1Universitätsklinikum des Saarlandes, Homburg, Saarland, 2Universitätsklinikum
des Saarlandes, Homburg, Germany, 3Baker Heart and Diabetes Institute,
Melbourne, Australia
Background: Ambulatory blood pressure monitoring (ABPM) is mandatory in every
patient with uncontrolled hypertension. Nighttime blood pressure and non-dipping is
associated with cardiovascular morbidity and mortality. Catheter-based renal sympathetic
denervation (RD) in patients with resistant hypertension has been shown to reduce
sympathetic drive and office blood pressure. The influence of RD on ambulatory blood
pressure (ABPM) has not been studied in details.
Methods: One-hundert patients with resistant hypertension undergoing catheter-based
renal denervation were included in the study. Systolic and diastolic blood pressure
(SBP/DBP) as well as ABPM (SBP/DBP average, SBP/DBP daytime, SBP/DBP
nighttime, heart rate (HR) average) and dipping-pattern were analyzed prior to, and at 3
and 6 months follow-up.
Results: RD reduced office SBP and DBP at 3 and 6 months by 22.9/8.1 mmHg and
26.6/9.3 mmHg (p for all 0.001), respectively. After 3 and 6 months 24-hour average
SBP/DBP was reduced by 8.9/4.9 mmHg (p0.019/0.025) and 11.9.5/6.9 mmHg
(p0.022/0.011), respectively. Average SBP/DBP were lowered at 3 and 6 months
follow-up at daytime by 9.6/5.1 mmHg (p0.010/0.001) and 12.1/8.1 mmHg (p0.001/
0.001) and at nighttime by 6.6/5.8 mmHg (p0.003/0.005) and 11.3/4.7 mmHg
(p0.001/0.001), respectively. Renal denervation also reduced maximum SBP by11.9
mmHg at 3 months and by 14.4 mmHg at 6 months follow-up (p0.009 and 0.006)
whereas maximum DBP was not changed.
Conclusions: Beside significant reductions in office SBP and DBP, RD also reduced
24-hour average, daytime and nighttime SBP and DBP as well as maximum SBP after 3
and 6 months.
TCT-212
First Report of the 6-Month First in Human results of the OneShot™ Renal
Denervation System: The RHAS Study
John Ormiston1, Timothy Watson2, Niels van Pelt3, Ralph Stewart2,
Peter Haworth2, James Stewart2, Mark Webster2
1Associate Professor, University of Auckland Medical School, Auckland, New
Zealand, 2Auckland City Hospital, Auckland, New Zealand, 3Middlemore Hospital,
Auckland, New Zealand
Background: Catheter-based selective renal sympathetic denervation has emerged as a
new therapeutic option for patients with resistant hypertension. Recent studies have shown
that ablation of the renal sympathetic nerves using radiofrequency (RF) energy delivered
from within the renal artery is safe and effective. The OneShot™ device (Covidien,
Campbell, CA) is a balloon-based RF system using a mounted spiral electrode with a
unique feature of irrigation of the vessel lumen during treatment. The non-compliant
balloon is inflated under low pressure (1 atm) in the renal artery. The electrode delivers
RF energy to ablate adjacent nerve bundles with a single 2-minute treatment.
Methods: The RHAS study was a single-center feasibility study performed at Mercy
Hospital in Auckland, New Zealand. Eligible patients had an office systolic blood pressure
(SBP) 160 mmHg (150 if diabetic) despite a drug regimen that included two or more
antihypertensive medications. Renal artery diameters were 4-7mm. The primary endpoint
was the ability to insert the OneShot™ device into each renal artery and deliver RF
energy. Secondary endpoints included office SBP at 6 months.
Results: Nine patients were enrolled; baseline characteristics and outcomes are shown
below. The technical success rate was 88.9%. One failure occurred in the first enrolled
patient and was due to an incorrect software setting which inhibited delivery of RF energy.
All remaining patients had both renal arteries treated with the OneShot™ device. The
mean procedure time (device insertion to end of treatment) was 16 minutes. At 30 days,
the mean office SBP was 155  19 mmHg, a change of 31  14 mmHg. Six-month
results are pending.
Characteristic/Outcome Mean  SD or % (n/N)
Age (yrs) 58.0 15.8
Male gender 55.6% (5/9)
Weight (kg) 84.1 16.5
# Anti-hypertensive meds 3.0 0.7
Serious adverse events 0.0% (0/8)
Office SBP at baseline (mmHg) 186 18
Office SBP at 1 month (mmHg) 155 19
Change from baseline (mmHg) 31 14
Office DBP at baseline (mmHg) 91 14
Office DBP at 1 month (mmHg) 86 14
Change from baseline (mmHg) 6 10
Conclusions: The RHAS trial demonstrated rapid delivery of RF energy for renal
sympathetic denervation using the OneShot™ device with safe blood pressure reduction
at 1 month. Six-month data will be available at time of presentation.
TCT-213
Safety And Efficacy Of A Novel Multi-Electrode Renal Denervation Catheter
In Resistant Hypertension: 3 Month Data From The EnligHTN I Trial
Stephen Worthley1, Costas Tsioufis2, Matthew Worthley3, Ajay Sinhal4,
Derek Chew4, Ian Meredith5, Yuvi Malaiapan6, Vasilios Papademetriou7
1The University of Adelaide, Adelaide, South Australia, 2Hippokratio Hospital,
Athens, Greece, 3University of Adelaide, Adelaide, SA, 4Flinders Medical Centre,
Adelaide, SA, 5Monash University, Melbourne, Australia, 6Monash Medical
Centre, Clayton, Victoria, 7Georgetown University, Washington DC, DC
Background: Catheter-based renal artery denervation therapy has emerged as a novel
therapy in patients with resistant hypertension (HTN). Although initially performed with
a single electrode radiofrequency (RF) catheter, recent advances in catheter designs are
using multiple pre-specified electrode positions. This theoretically could improve the
safety and efficacy of this treatment. We present the 3-month safety and efficacy data from
the international multicenter EnligHTN I trial.
Methods: Inclusion criteria include patients from 18-80 years of age with office systolic
BP 160 mmHg (150 for patients with Type 2 diabetes) on  3 anti HTN agents
(including a diuretic) and renal artery diameter 4mm and length 20mm. Patients with
dual main renal arteries are excluded. The primary end-point is the change in office BP at
6 months from baseline. The safety endpoints include vascular and renal artery
complications. Renal artery CT angiography is performed at baseline and repeated at 6
months. Utilizing femoral artery access with an 8Fr RDC guiding sheath the EnligHTN
catheter is introduced into the renal artery, and RF energy delivered sequentially for 90
seconds per electrode. The catheter is repositioned, rotated and denervation repeated. Both
renal arteries are treated.
Results: In total 46 patients underwent renal denervation. Mean age was 6010
yrs and baseline BP 176/96 mmHg. The median procedure time (from initiation to
completion of RF delivery) was 34.0 min. The mean number of therapies
delivered was 7.7 for the right and 7.4 for the left renal arteries. There was no
change in renal function pre and post procedure (eGFR 76 and 75 mL/min/1.73m2
respectively). There were no renal artery or serious vascular complications
through 3 months. The BP changes pre-discharge and at 1 month were 23/
9(n45, p0.0001) and 28/10 mmHg respectively(n46, p0.0001). The
preliminary 3-month BP change is 37/17 mmHg(n24, p0.0001).
Conclusions: Renal denervation was performed safely and swiftly in patients with
resistant HTN using the EnligHTN catheter. Initial results show a significant early
reduction in BP that continues to reduce further at 3 months.
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